A5083740899- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Colorectal Cancer Screening and Detection
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Anorectal Disease Treatments and Outcomes
- Radiomics and Machine Learning in Medical Imaging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Intraperitoneal and Appendiceal Malignancies
- Ovarian cancer diagnosis and treatment
- Pancreatic and Hepatic Oncology Research
- Cancer, Hypoxia, and Metabolism
- Radiation Therapy and Dosimetry
- Cancer, Lipids, and Metabolism
- Multiple and Secondary Primary Cancers
- Appendicitis Diagnosis and Management
- Epigenetics and DNA Methylation
- Gastrointestinal Tumor Research and Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Cancer Research and Treatments
Memorial Sloan Kettering Cancer Center
2016-2025
Society for Vascular Surgery
2023
Cornell University
1998-2023
Beijing Institute of Genomics
2023
Chinese Academy of Sciences
2023
University of New Haven
2023
Kettering University
1995-2022
HealthPartners
2022
Emory University
2018
Yale University
2018
PURPOSE Prospective data on the efficacy of a watch-and-wait strategy to achieve organ preservation in patients with locally advanced rectal cancer treated total neoadjuvant therapy are limited. METHODS In this prospective, randomized phase II trial, we assessed outcomes 324 stage or III adenocarcinoma induction chemotherapy followed by chemoradiotherapy (INCT-CRT) consolidation (CRT-CNCT) and either mesorectal excision (TME) basis tumor response. Patients both groups received 4 months...
<h3>Importance</h3> Treatment of locally advanced rectal (LARC) cancer involves chemoradiation, surgery, and chemotherapy. The concept total neoadjuvant therapy (TNT), in which chemoradiation chemotherapy are administered prior to has been developed optimize delivery effective systemic aimed at micrometastases. <h3>Objective</h3> To compare the traditional approach preoperative (chemoRT) followed by postoperative adjuvant with more recent TNT for LARC. <h3>Design, Setting, Participants</h3>...
The watch-and-wait (WW) strategy aims to spare patients with rectal cancer unnecessary resection.To analyze the outcomes of WW among who had a clinical complete response neoadjuvant therapy.This retrospective case series analysis conducted at comprehensive center in New York included received diagnosis adenocarcinoma between January 1, 2006, and 31, 2015. median follow-up was 43 months. Data analyses were from June 2016, October 2018.Patients after completing therapy agreed active...
Although neoadjuvant chemoradiotherapy achieves low local recurrence rates in clinical stages II to III rectal cancer, it delays administration of optimal chemotherapy. We evaluated preoperative infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/bevacizumab with selective rather than consistent use chemoradiotherapy.Thirty-two patients cancer participated this single-center phase trial. All were candidates for anterior resection total mesorectal excision (TME). Patients receive...
In Brief Objective: Our aims were to (1) determine the long-term oncologic outcome for patients with rectal cancer treated preoperative combined modality therapy (CMT) followed by total mesorectal excision (TME), (2) identify factors predictive of outcome, and (3) significance extent pathologic tumor response. Summary Background Data: Locally advanced (T3–4 and/or N1) adenocarcinoma is commonly CMT TME. However, results this approach a durable remain largely unknown. Methods: Two hundred...
During disease progression the cells that comprise solid malignancies undergo significant changes in gene copy number and chromosome structure. Colorectal cancer provides an excellent model to study this process. To indentify characterize chromosomal abnormalities colorectal cancer, we performed a statistical analysis of 299 expression 130 SNP arrays profiled at different stages disease, including normal tissue, adenoma, 1–4 adenocarcinoma, metastasis. We identified broad (> 1/2 arm)...
In Brief Introduction: Nonoperative management (NOM) of rectal cancer after a complete clinical response (cCR) to neoadjuvant therapy is controversial. this article, we retrospectively reviewed the outcomes patients managed with selective NOM cCR treatment and compared these who underwent standard resection pathological (pCR). Methods: Patients completing chemoradiotherapy (CRT) for stage I III between January 2006 August 2010 were reviewed. Median follow-up was calculated in months...
Treatment of patients with non-metastatic, locally advanced rectal cancer (LARC) includes pre-operative chemoradiation, total mesorectal excision (TME) and post-operative adjuvant chemotherapy. This trimodality treatment provides local tumor control in most patients; but almost one-third ultimately die from distant metastasis. Most survivors experience significant impairment quality life (QoL), due primarily to removal the rectum. A current challenge lies identifying who could safely undergo...
Appendiceal tumors exhibiting both neuroendocrine and glandular differentiation are uncommon have caused difficulty in pathologic classification, prediction of prognosis, clinical management. Previously, such lesions been variously designated as adenocarcinoid, goblet cell carcinoid (GCC), mixed adenocarcinoma carcinoid. In this study, we undertook a retrospective investigation 63 cases classified them typical GCC (group A) ex on the basis histologic features tumor at primary site. The group...
PURPOSE To determine the conversion to resectability in patients with unresectable liver metastases from colorectal cancer treated hepatic arterial infusion (HAI) plus systemic oxaliplatin and irinotecan (CPT-11). PATIENTS AND METHODS Forty-nine (53% previously chemotherapy) were enrolled onto a phase I protocol HAI floxuridine dexamethasone chemotherapy irinotecan. Results Ninety-two percent of 49 had complete (8%) or partial (84%) response, 23 (47%) able undergo resection group extensive...
Tyrosine phosphorylation plays a critical role in regulating cellular function and is central feature signaling cascades involved oncogenesis. The regulation of tyrosine coordinately controlled by kinases phosphatases (PTPs). Whereas activation has been shown to play vital roles tumor development, the PTPs much less well defined. Here, we show that receptor protein phosphatase delta (PTPRD) frequently inactivated glioblastoma multiforme (GBM), deadly primary neoplasm brain. PTPRD target...
Mutations in RAS proteins occur widely human cancer. Prompted by the confirmation of KRAS mutation as a predictive biomarker response to epidermal growth factor receptor (EGFR)-targeted therapies, limited clinical testing for pathway mutations has recently been adopted. We performed multiplatform genomic analysis characterize, nonbiased manner, biological, biochemical, and prognostic significance Ras alterations colorectal tumors other solid tumor malignancies. exon 4 were found commonly...
To compare the mutational and copy number profiles of primary metastatic colorectal carcinomas (CRCs) using both unpaired paired samples derived from disease sites.We performed a multiplatform genomic analysis 736 fresh frozen CRC tumors 613 patients. The cohort included 84 patients in whom tumor tissue sites was available 31 with pairs metastases. Tumors were analyzed for mutations KRAS, NRAS, BRAF, PIK3CA, TP53 genes, discordant results between further investigated by analyzing...
Abstract Because Notch signaling is implicated in colon cancer tumorigenesis and protects cells from apoptosis by inducing prosurvival targets, it was hypothesized that inhibition of with γ-secretase inhibitors (GSI) may enhance the chemosensitivity cells. We first show Notch-1 receptor, as well its downstream target Hes-1, up-regulated progression, similar to other genes involved chemoresistance. then report chemotherapy induces Notch-1, oxaliplatin, 5-fluorouracil (5-FU), or SN-38 (the...
Tumor regression grade (TRG) is a measure of histopathological response rectal cancer to neoadjuvant chemoradiation and associated with outcomes. Several TRG systems are used: Mandard (5,3-tier), Dowrak/Rödel Memorial Sloan Kettering Cancer Center (MSKCC), American Joint Committee on (AJCC) Staging. A single would assist in comparing results across institutions, designing future studies. In this study, the predictive accuracies various published classification schemes compared.Review...
The oligometastasis hypothesis suggests a spectrum of metastatic virulence where some metastases are limited in extent and curable with focal therapies. A subset patients colorectal cancer achieves prolonged survival after resection liver consistent oligometastasis. Here we define three robust subtypes de novo metastasis through integrative molecular analysis. Patients exhibiting MSI-independent immune activation experience the most favorable survival. Subtypes adverse outcomes demonstrate...
Standard therapy for locally advanced rectal cancer (LARC) is preoperative chemoradiotherapy and postoperative chemotherapy. At Memorial Sloan-Kettering Cancer Center (MSKCC) the authors began offering FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) as initial treatment patients with high-risk LARC to target micrometastases while treating primary tumor. The purpose of this study report safety efficacy given before on tumor downsizing pathologic complete response (pathCR) in LARC. records...
Guidelines recommend measuring preoperative carcinoembryonic antigen (CEA) in patients with colon cancer. Although persistently elevated CEA after surgery has been associated increased risk for metastatic disease, prognostic significance of that normalized resection is unknown.To investigate whether normalizes cancer have a higher recurrence than normal CEA.This retrospective cohort analysis was conducted at comprehensive center. Consecutive who underwent curative stage I to III...
Evaluate conversion rate of patients with unresectable colorectal-liver metastasis to complete resection hepatic-arterial infusion plus systemic chemotherapy including bevacizumab (Bev).Forty-nine colorectal liver metastases (CRLM) were included in a single-institution phase II trial. Conversion was the primary outcome. Secondary outcomes overall survival (OS), progression-free survival, and response rates. Multivariate landmark analyses performed evaluate differences between resected...
Abstract Purpose: Evaluate response of mismatch repair–deficient (dMMR) rectal cancer to neoadjuvant chemotherapy. Experimental Design: dMMR tumors at Memorial Sloan Kettering Cancer Center (New York, NY) were retrospectively reviewed for characteristics, treatment, and outcomes. Fifty patients with identified by IHC and/or microsatellite instability analysis, initial treatment compared a matched MMR-proficient (pMMR) cohort. Germline somatic mutation analyses evaluated. Patient-derived...
JCO